{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T03:22:57Z","timestamp":1764645777065,"version":"3.40.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Translational Research Grant of HCRCH","award":["2020ZKMB06"],"award-info":[{"award-number":["2020ZKMB06"]}]},{"name":"the Xingliao Talents Program","award":["xlyc1807265"],"award-info":[{"award-number":["xlyc1807265"]}]},{"name":"Liaoning Province Central Guidance Special Project for Local Science and Technology Development","award":["2023JH6\/100200006"],"award-info":[{"award-number":["2023JH6\/100200006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02476-9","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T02:04:07Z","timestamp":1744682647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative efficacy and safety in low-intensity treatment for acute myeloid leukemia in older patients: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"30","author":[{"given":"Wenze","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijing","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengjie","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weilin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"issue":"2","key":"2476_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.blre.2016.09.005","volume":"31","author":"NA Podoltsev","year":"2017","unstructured":"Podoltsev NA, Stahl M, Zeidan AM, Gore SD. Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Rev. 2017;31(2):43\u201362. https:\/\/doi.org\/10.1016\/j.blre.2016.09.005.","journal-title":"Blood Rev"},{"issue":"2","key":"2476_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3324\/haematol.2022.280803","volume":"108","author":"RF Schlenk","year":"2023","unstructured":"Schlenk RF. Acute myeloid leukemia: introduction to a series highlighting progress and ongoing challenges. Haematologica. 2023;108(2):306\u20137. https:\/\/doi.org\/10.3324\/haematol.2022.280803.","journal-title":"Haematologica"},{"issue":"5","key":"2476_CR3","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1365-2141.2010.08470.x","volume":"152","author":"DA Pollyea","year":"2011","unstructured":"Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol. 2011;152(5):524\u201342. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08470.x.","journal-title":"Br J Haematol"},{"issue":"22","key":"2476_CR4","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","volume":"116","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Ravandi F, O\u2019Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70\u00a0years or older) with acute myeloid leukemia. Blood. 2010;116(22):4422\u20139. https:\/\/doi.org\/10.1182\/blood-2010-03-276485.","journal-title":"Blood"},{"issue":"5","key":"2476_CR5","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/cncr.21723","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, O\u2019Brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E. Results of intensive chemotherapy in 998 patients age 65\u00a0years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106(5):1090\u20138. https:\/\/doi.org\/10.1002\/cncr.21723.","journal-title":"Cancer"},{"issue":"7","key":"2476_CR6","doi-asserted-by":"publisher","first-page":"e535","DOI":"10.1016\/s2352-3026(22)00167-3","volume":"9","author":"NJ Short","year":"2022","unstructured":"Short NJ, Kantarjian H. Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia. Lancet Haematol. 2022;9(7):e535\u201345. https:\/\/doi.org\/10.1016\/s2352-3026(22)00167-3.","journal-title":"Lancet Haematol"},{"issue":"6","key":"2476_CR7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2141.2012.09213.x","volume":"158","author":"RK Hills","year":"2012","unstructured":"Hills RK. The contribution of randomized trials to the cure of haematological disorders from Bradford hill onwards. Br J Haematol. 2012;158(6):691\u20139. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09213.x.","journal-title":"Br J Haematol"},{"issue":"4","key":"2476_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/ajh.26079","volume":"96","author":"JE Cortes","year":"2021","unstructured":"Cortes JE, Mehta P. Determination of fitness and therapeutic options in older patients with acute myeloid leukemia. Am J Hematol. 2021;96(4):493\u2013507. https:\/\/doi.org\/10.1002\/ajh.26079.","journal-title":"Am J Hematol"},{"issue":"24","key":"2476_CR9","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1200\/jco.2014.55.1564","volume":"32","author":"HD Klepin","year":"2014","unstructured":"Klepin HD, Rao AV, Pardee TS. Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(24):2541\u201352. https:\/\/doi.org\/10.1200\/jco.2014.55.1564.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"2476_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/17474086.2023.2184342","volume":"16","author":"R Babakhanlou","year":"2023","unstructured":"Babakhanlou R, Ravandi-Kashani F. Non-intensive acute myeloid leukemia therapies for older patients. Expert Rev Hematol. 2023;16(3):171\u201380. https:\/\/doi.org\/10.1080\/17474086.2023.2184342.","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"2476_CR11","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(3):502\u201326. https:\/\/doi.org\/10.1002\/ajh.26822.","journal-title":"Am J Hematol"},{"key":"2476_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-1-0716-1566-9_12","volume":"2345","author":"J Watt","year":"2022","unstructured":"Watt J, Del Giovane C. Network meta-analysis. Method Mol Biol. 2022;2345:187\u2013201. https:\/\/doi.org\/10.1007\/978-1-0716-1566-9_12.","journal-title":"Method Mol Biol"},{"issue":"11","key":"2476_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\u00e1-L\u00f3pez F, G\u00f8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384. https:\/\/doi.org\/10.7326\/m14-2385.","journal-title":"Ann Intern Med"},{"key":"2476_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2914","volume":"346","author":"EJ Mills","year":"2013","unstructured":"Mills EJ, Thorlund K, Ioannidis JP. Demystifying trial networks and network meta-analysis. BMJ (Clin Res ed). 2013;346: f2914. https:\/\/doi.org\/10.1136\/bmj.f2914.","journal-title":"BMJ (Clin Res ed)"},{"issue":"5","key":"2476_CR15","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/0272989x12455847","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Mak Int J Soc Med Decis Mak. 2013;33(5):641\u201356. https:\/\/doi.org\/10.1177\/0272989x12455847.","journal-title":"Med Decis Mak Int J Soc Med Decis Mak"},{"key":"2476_CR16","unstructured":"Dias S, Sutton AJ, Welton NJ, Ades AE. NICE decision support unit technical support documents. In: Heterogeneity: subgroups, meta-regression, bias and bias-adjustment national institute for health and care excellence (NICE) Copyright\u00a9. National Institute for Health and Clinical Excellence: London. 2012."},{"key":"2476_CR17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/978-1-62703-059-5_25","volume":"930","author":"FY Bois","year":"2013","unstructured":"Bois FY. Bayesian inference. Method Mol Biol (Clifton NJ). 2013;930:597\u2013636. https:\/\/doi.org\/10.1007\/978-1-62703-059-5_25.","journal-title":"Method Mol Biol (Clifton NJ)"},{"issue":"2","key":"2476_CR18","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/ije\/dyt043","volume":"42","author":"G Hamra","year":"2013","unstructured":"Hamra G, MacLehose R, Richardson D. Markov chain Monte Carlo: an introduction for epidemiologists. Int J Epidemiol. 2013;42(2):627\u201334. https:\/\/doi.org\/10.1093\/ije\/dyt043.","journal-title":"Int J Epidemiol"},{"issue":"10","key":"2476_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS ONE. 2013;8(10): e76654. https:\/\/doi.org\/10.1371\/journal.pone.0076654.","journal-title":"PLoS ONE"},{"issue":"1","key":"2476_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s12936-017-1963-0","volume":"16","author":"S Whegang Youdom","year":"2017","unstructured":"Whegang Youdom S, Tahar R, Basco LK. Comparison of anti-malarial drugs efficacy in the treatment of uncomplicated malaria in African children and adults using network meta-analysis. Malar J. 2017;16(1):311. https:\/\/doi.org\/10.1186\/s12936-017-1963-0.","journal-title":"Malar J"},{"issue":"10","key":"2476_CR21","doi-asserted-by":"publisher","first-page":"666","DOI":"10.7326\/m15-2521","volume":"164","author":"L Trinquart","year":"2016","unstructured":"Trinquart L, Attiche N, Bafeta A, Porcher R, Ravaud P. Uncertainty in treatment rankings: reanalysis of network meta-analyses of randomized trials. Ann Intern Med. 2016;164(10):666\u201373. https:\/\/doi.org\/10.7326\/m15-2521.","journal-title":"Ann Intern Med"},{"key":"2476_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58. https:\/\/doi.org\/10.1186\/s12874-015-0060-8.","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"2476_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000617","volume":"5","author":"H D\u00f6hner","year":"2021","unstructured":"D\u00f6hner H, Symeonidis A, Deeren D, Demeter J, Sanz MA, Anagnostopoulos A, Esteve J, Fiedler W, Porkka K, Kim HJ, Lee JH, Usuki K, D\u2019Ardia S, Won Jung C, Salamero O, Horst HA, Recher C, Rousselot P, Sandhu I, Theunissen K, Thol F, D\u00f6hner K, Teleanu V, DeAngelo DJ, Naoe T, Sekeres MA, Belsack V, Ge M, Taube T, Ottmann OG. Adjunctive volasertib in patients with acute myeloid leukemia not eligible for standard induction therapy: a randomized, phase 3 trial. HemaSphere. 2021;5(8): e617. https:\/\/doi.org\/10.1097\/hs9.0000000000000617.","journal-title":"HemaSphere"},{"issue":"8","key":"2476_CR24","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/ajh.26206","volume":"96","author":"TM Kadia","year":"2021","unstructured":"Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2021;96(8):914\u201324. https:\/\/doi.org\/10.1002\/ajh.26206.","journal-title":"Am J Hematol"},{"issue":"1","key":"2476_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.clml.2013.09.007","volume":"14","author":"XG Thomas","year":"2014","unstructured":"Thomas XG, Arthur C, Delaunay J, Jones M, Berrak E, Kantarjian HM. A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014;14(1):68\u201372. https:\/\/doi.org\/10.1016\/j.clml.2013.09.007.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2476_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/167029","volume":"2015","author":"LA Jacob","year":"2015","unstructured":"Jacob LA, Aparna S, Lakshmaiah KC, Lokanatha D, Babu G, Babu S, Appachu S. Decitabine compared with low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia: a pilot study of safety, efficacy, and cost-effectiveness. Adv Hematol. 2015;2015: 167029. https:\/\/doi.org\/10.1155\/2015\/167029.","journal-title":"Adv Hematol"},{"issue":"1","key":"2476_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jjco\/hyab170","volume":"52","author":"K Yamamoto","year":"2022","unstructured":"Yamamoto K, Shinagawa A, DiNardo CD, Pratz KW, Ishizawa K, Miyamoto T, Komatsu N, Nakashima Y, Yoshida C, Fukuhara N, Usuki K, Yamauchi T, Asada N, Asou N, Choi I, Miyazaki Y, Honda H, Okubo S, Kurokawa M, Zhou Y, Zha J, Potluri J, Matsumura I. Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Jpn J Clin Oncol. 2022;52(1):29\u201338. https:\/\/doi.org\/10.1093\/jjco\/hyab170.","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"2476_CR28","doi-asserted-by":"publisher","first-page":"7175","DOI":"10.1002\/cam4.5459","volume":"12","author":"L Laloi","year":"2023","unstructured":"Laloi L, Billotey NC, Dumas PY, Paul F, Villate A, Simand C, Fornecker L, Puisset F, Bertoli S, Simonet MB, Laribi K, Houyou D, Santagostino A, Michel C, Guepin GR, Guerineau E, Tabrizi R, Hunault M, Giltat A, Kaphan E, Bulabois C, Cartet E, Rocher C, Lachenal F, Morisset S, R\u00e9cher C, Pigneux A, Belhabri A, Michallet M, Michallet AS. Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy. Cancer Med. 2023;12(6):7175\u201381. https:\/\/doi.org\/10.1002\/cam4.5459.","journal-title":"Cancer Med"},{"issue":"5","key":"2476_CR29","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.21873\/anticanres.17003","volume":"44","author":"Y Baba","year":"2024","unstructured":"Baba Y, Hida N, Sambe T, Abe M, Kabasawa N, Sakai H, Yoshimura K, Fukuda T. Efficacy of venetoclax and azacitidine in acute myeloid leukemia compared to azacitidine monotherapy: real-world experience. Anticancer Res. 2024;44(5):2003\u20137. https:\/\/doi.org\/10.21873\/anticanres.17003.","journal-title":"Anticancer Res"},{"issue":"4","key":"2476_CR30","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/ejh.14140","volume":"112","author":"C Petit","year":"2024","unstructured":"Petit C, Saillard C, Mohty B, Hicheri Y, Villetard F, Maisano V, Charbonnier A, Rey J, D\u2019Incan E, Rouzaud C, Gelsi-Boyer V, Murati A, Lhoumeau AC, Ittel A, Mozziconacci MJ, Alary AS, Hospital MA, Vey N, Garciaz S. Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients. Eur J Haematol. 2024;112(4):530\u20137. https:\/\/doi.org\/10.1111\/ejh.14140.","journal-title":"Eur J Haematol"},{"issue":"4","key":"2476_CR31","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, D\u00f6hner H, R\u00e9cher C, Fiedler W, Yamamoto K, Wang J, Yoon SS, Wolach O, Yeh SP, Leber B, Esteve J, Mayer J, Porkka K, Ill\u00e9s \u00c1, Lemoli RM, Turgut M, Ku G, Miller C, Zhou Y, Zhang M, Chyla B, Potluri J, DiNardo CD. Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99(4):615\u201324. https:\/\/doi.org\/10.1002\/ajh.27246.","journal-title":"Am J Hematol"},{"issue":"6","key":"2476_CR32","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/leu.2015.38","volume":"29","author":"AK Burnett","year":"2015","unstructured":"Burnett AK, Russell N, Hills RK, Panoskaltsis N, Khwaja A, Hemmaway C, Cahalin P, Clark RE, Milligan D. A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia. Leukemia. 2015;29(6):1312\u20139. https:\/\/doi.org\/10.1038\/leu.2015.38.","journal-title":"Leukemia"},{"issue":"10","key":"2476_CR33","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1007\/s00277-020-04217-w","volume":"99","author":"S Pepe","year":"2020","unstructured":"Pepe S, Scalzulli E, Colafigli G, Di Prima A, Diverio D, Mancini M, Latagliata R, Martelli M, Fo\u00e0 R, Breccia M. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience. Ann Hematol. 2020;99(10):2405\u201316. https:\/\/doi.org\/10.1007\/s00277-020-04217-w.","journal-title":"Ann Hematol"},{"key":"2476_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/HS9.0000000000000404","volume":"4","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, et al. A phase 3 study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (viale-C): a 6\u00a0month update. HemaSphere. 2020;4:19\u201320. https:\/\/doi.org\/10.1097\/HS9.0000000000000404.","journal-title":"HemaSphere"},{"issue":"5","key":"2476_CR35","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00277-021-04465-4","volume":"100","author":"M Heuser","year":"2021","unstructured":"Heuser M, Smith BD, Fiedler W, Sekeres MA, Montesinos P, Leber B, Merchant A, Papayannidis C, P\u00e9rez-Sim\u00f3n JA, Hoang CJ, et al. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Ann Hematol. 2021;100(5):1181\u201394. https:\/\/doi.org\/10.1007\/s00277-021-04465-4.","journal-title":"Ann Hematol"},{"issue":"17","key":"2476_CR36","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1182\/blood.2021014586","volume":"140","author":"ES Wang","year":"2022","unstructured":"Wang ES, Montesinos P, Minden MD, Lee JH, Heuser M, Naoe T, Chou WC, Laribi K, Esteve J, Altman JK, Havelange V, Watson AM, Gambacorti-Passerini C, Patkowska E, Liu S, Wu R, Philipose N, Hill JE, Gill SC, Rich ES, Tiu RV. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. 2022;140(17):1845\u201357. https:\/\/doi.org\/10.1182\/blood.2021014586.","journal-title":"Blood"},{"issue":"1","key":"2476_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/leu.2012.229","volume":"27","author":"AK Burnett","year":"2013","unstructured":"Burnett AK, Hills RK, Hunter AE, Milligan D, Kell WJ, Wheatley K, Yin J, McMullin MF, Dignum H, Bowen D, et al. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia. 2013;27(1):75\u201381. https:\/\/doi.org\/10.1038\/leu.2012.229.","journal-title":"Leukemia"},{"issue":"2","key":"2476_CR38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","volume":"33","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, Montesinos P, Pollyea DA, DesJardins P, Ottmann O, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33(2):379\u201389. https:\/\/doi.org\/10.1038\/s41375-018-0312-9.","journal-title":"Leukemia"},{"issue":"19","key":"2476_CR39","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1182\/blood-2014-10-608117","volume":"125","author":"M Dennis","year":"2015","unstructured":"Dennis M, Russell N, Hills RK, Hemmaway C, Panoskaltsis N, McMullin MF, Kjeldsen L, Dignum H, Thomas IF, Clark RE, et al. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood. 2015;125(19):2923\u201332. https:\/\/doi.org\/10.1182\/blood-2014-10-608117.","journal-title":"Blood"},{"issue":"7","key":"2476_CR40","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, D\u00f6hner H, Letai A, Fenaux P, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971.","journal-title":"N Engl J Med"},{"issue":"9","key":"2476_CR41","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1182\/blood-2014-03-560557","volume":"124","author":"H D\u00f6hner","year":"2014","unstructured":"D\u00f6hner H, L\u00fcbbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood. 2014;124(9):1426\u201333. https:\/\/doi.org\/10.1182\/blood-2014-03-560557.","journal-title":"Blood"},{"issue":"7","key":"2476_CR42","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1182\/bloodadvances.2021006138","volume":"6","author":"AM Zeidan","year":"2022","unstructured":"Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Hellmann A, Taussig DC, Tormo M, et al. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Blood Adv. 2022;6(7):2219\u201329. https:\/\/doi.org\/10.1182\/bloodadvances.2021006138.","journal-title":"Blood Adv"},{"key":"2476_CR43","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8691835","author":"W Wang","year":"2022","unstructured":"Wang W, Luo Q, Chen Q, Pang A, Fang K. Analysis of the clinical efficacy of azacytidine + venetoclax in the treatment of elderly patients with relapsed refractory acute myeloid leukemia. Evid Based Complement Altern Med. 2022. https:\/\/doi.org\/10.1155\/2022\/8691835.","journal-title":"Evid Based Complement Altern Med"},{"issue":"24","key":"2476_CR44","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1182\/bloodadvances.2018023689","volume":"2","author":"GJ Roboz","year":"2018","unstructured":"Roboz GJ, Mandrekar SJ, Desai P, Laumann K, Walker AR, Wang ES, Kolitz JE, Powell BL, Attar EC, Stock W, et al. Randomized trial of 10 days of decitabine 6 bortezomib in untreated older patients with AML: CALGB 11002 (alliance). Blood Adv. 2018;2(24):3608\u201317. https:\/\/doi.org\/10.1182\/bloodadvances.2018023689.","journal-title":"Blood Adv"},{"issue":"14","key":"2476_CR45","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1002\/cncr.28113","volume":"119","author":"HM Kantarjian","year":"2013","unstructured":"Kantarjian HM, Martinelli G, Jabbour EJ, Quint\u00e1s-Cardama A, Ando K, Bay JO, Wei A, Gr\u00f6pper S, Papayannidis C, Owen K, et al. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer. 2013;119(14):2611\u20139. https:\/\/doi.org\/10.1002\/cncr.28113.","journal-title":"Cancer"},{"issue":"18","key":"2476_CR46","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1182\/BLOODADVANCES.2020002846","volume":"4","author":"G Huls","year":"2020","unstructured":"Huls G, Chitu DA, Pabst T, Klein SK, Stussi G, Griskevicius L, Valk PJM, Cloos J, van de Loosdrecht AA, Breems D, van Lammeren-Venema D, van Zeventer I, Boersma R, Jongen-Lavrencic M, Fehr M, Hoogendoorn M, Manz MG, S\u00f6hne M, Kooy RVM, Deeren D, van der Poel MWM, Legdeur MC, Tick L, Chalandon Y, Ammatuna E, Blum S, L\u00f6wenberg B, Ossenkoppele GJ. Ibrutinib added to 10\u00a0day decitabine for older patients with AML and higher risk MDS. Blood Adv. 2020;4(18):4267\u201377. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2020002846.","journal-title":"Blood Adv"},{"issue":"4","key":"2476_CR47","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3760\/cma.j.issn.0253-2727.2021.04.004","volume":"42","author":"Y Hu","year":"2021","unstructured":"Hu Y, Jin J, Zhang Y, Hu JD, Li JM, Wei XD, Gao SJ, Zha JH, Jiang Q, Wu J, et al. Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial. Zhonghua Xue Ye Xue Za Zhi. 2021;42(4):288\u201394. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2021.04.004.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"1","key":"2476_CR48","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00277-022-05025-0","volume":"101","author":"AF Berdel","year":"2022","unstructured":"Berdel AF, Koch R, Gerss J, Hentrich M, Peceny R, Bartscht T, Steffen B, Bischoff M, Spiekermann K, Angenendt L, Mikesch JH, Kewitz T, Butterfass-Bahloul T, Serve H, Lenz G, Berdel WE, Krug U, Schliemann C. A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy. Ann Hematol. 2022;101(1):63\u201372. https:\/\/doi.org\/10.1007\/s00277-022-05025-0.","journal-title":"Ann Hematol"},{"issue":"1","key":"2476_CR49","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41375-020-0773-5","volume":"35","author":"P Montesinos","year":"2021","unstructured":"Montesinos P, Roboz GJ, Bulabois CE, Subklewe M, Platzbecker U, Ofran Y, Papayannidis C, Wierzbowska A, Shin HJ, Doronin V, et al. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2\/3 study. Leukemia. 2021;35(1):62\u201374. https:\/\/doi.org\/10.1038\/s41375-020-0773-5.","journal-title":"Leukemia"},{"issue":"12","key":"2476_CR50","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.jval.2023.09.001","volume":"26","author":"X Li","year":"2023","unstructured":"Li X, Suh HS, Lachaine J, Schuh AC, Pratz K, Betts KA, Song J, Dua A, Bui CN. Comparative efficacy of venetoclax-based combination therapies and other therapies in treatment-naive patients with acute myeloid leukemia ineligible for intensive chemotherapy: a network meta-analysis. Value Health J Int Soc Pharmacoecon Outcome Res. 2023;26(12):1689\u201396. https:\/\/doi.org\/10.1016\/j.jval.2023.09.001.","journal-title":"Value Health J Int Soc Pharmacoecon Outcome Res"},{"key":"2476_CR51","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2147\/ceor.S203482","volume":"11","author":"G Tremblay","year":"2019","unstructured":"Tremblay G, Westley T, Cappelleri JC, Arondekar B, Chan G, Bell TJ, Briggs A. Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons. Clin Econ Outcome Res CEOR. 2019;11:551\u201365. https:\/\/doi.org\/10.2147\/ceor.S203482.","journal-title":"Clin Econ Outcome Res CEOR"},{"issue":"1","key":"2476_CR52","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/hematology.2021000309","volume":"2021","author":"F Thol","year":"2021","unstructured":"Thol F. What to use to treat AML: the role of emerging therapies. Hematology Am Soc Hematol Educ Program. 2021;2021(1):16\u201323. https:\/\/doi.org\/10.1182\/hematology.2021000309.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"2476_CR53","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","volume":"33","author":"BA Jonas","year":"2019","unstructured":"Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019;33(12):2795\u2013804. https:\/\/doi.org\/10.1038\/s41375-019-0612-8.","journal-title":"Leukemia"},{"issue":"2","key":"2476_CR54","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1182\/bloodadvances.2023011106","volume":"8","author":"C Jimenez-Chillon","year":"2024","unstructured":"Jimenez-Chillon C, Othman J, Taussig D, Jimenez-Vicente C, Martinez-Roca A, Tiong IS, Jain M, Aries J, Cakmak S, Knapper S, Kristensen DT, Murthy V, Galani JZ, Kallmeyer C, Ngu L, Veale D, Bolam S, Orfali N, Parker A, Manson C, Parker J, Erblich T, Richardson D, Mokretar K, Potter N, Overgaard UM, Roug AS, Wei AH, Esteve J, J\u00e4dersten M, Russell N, Dillon R. Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML. Blood Adv. 2024;8(2):343\u201352. https:\/\/doi.org\/10.1182\/bloodadvances.2023011106.","journal-title":"Blood Adv"},{"issue":"13","key":"2476_CR55","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1158\/1078-0432.Ccr-21-3405","volume":"28","author":"M Konopleva","year":"2022","unstructured":"Konopleva M, Thirman MJ, Pratz KW, Garcia JS, Recher C, Pullarkat V, Kantarjian HM, DiNardo CD, Dail M, Duan Y, Chyla B, Potluri J, Miller CL, Wei AH. Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-na\u00efve acute myeloid leukemia. Clin Cancer Res Off J Am Assoc Cancer Res. 2022;28(13):2744\u201352. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-3405.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"2476_CR56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40364-021-00288-7","volume":"9","author":"X Zhang","year":"2021","unstructured":"Zhang X, Qian J, Wang H, Wang Y, Zhang Y, Qian P, Lou Y, Jin J, Zhu H. Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia. Biomarker Res. 2021;9(1):30. https:\/\/doi.org\/10.1186\/s40364-021-00288-7.","journal-title":"Biomarker Res"},{"key":"2476_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18788","author":"Y Liu","year":"2023","unstructured":"Liu Y, Zhu L, Lv Z, Mao L, Hu C, Wang J, Zhou Y, Jin J, Meng H, You L. Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukaemia in routine clinical practice. Br J Haematol. 2023. https:\/\/doi.org\/10.1111\/bjh.18788.","journal-title":"Br J Haematol"},{"issue":"6","key":"2476_CR58","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.stem.2009.03.015","volume":"4","author":"J Gao","year":"2009","unstructured":"Gao J, Graves S, Koch U, Liu S, Jankovic V, Buonamici S, El Andaloussi A, Nimer SD, Kee BL, Taichman R, Radtke F, Aifantis I. Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell. 2009;4(6):548\u201358. https:\/\/doi.org\/10.1016\/j.stem.2009.03.015.","journal-title":"Cell Stem Cell"},{"issue":"10","key":"2476_CR59","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/cas.13019","volume":"107","author":"N Fukushima","year":"2016","unstructured":"Fukushima N, Minami Y, Kakiuchi S, Kuwatsuka Y, Hayakawa F, Jamieson C, Kiyoi H, Naoe T. Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci. 2016;107(10):1422\u20139. https:\/\/doi.org\/10.1111\/cas.13019.","journal-title":"Cancer Sci"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02476-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02476-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02476-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T14:48:13Z","timestamp":1744728493000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02476-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2476"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02476-9","relation":{},"ISSN":["2047-783X"],"issn-type":[{"type":"electronic","value":"2047-783X"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This meta-analysis strictly follows academic norms and ethical principles, performing only a secondary analysis of aggregated data. The privacy and confidentiality of study participants in the original research were not compromised. All included studies were retrieved from scientific databases and subjected to rigorous quality assessments to ensure reliability and validity.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"280"}}